TaiMed Biologics Balance Sheet Health
Financial Health criteria checks 5/6
TaiMed Biologics has a total shareholder equity of NT$4.1B and total debt of NT$502.0M, which brings its debt-to-equity ratio to 12.1%. Its total assets and total liabilities are NT$5.7B and NT$1.6B respectively.
Key information
12.1%
Debt to equity ratio
NT$501.99m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$2.18b |
| Equity | NT$4.15b |
| Total liabilities | NT$1.59b |
| Total assets | NT$5.73b |
Recent financial health updates
Recent updates
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook
Apr 20
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%
Mar 16TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.
Feb 09Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven
Jan 05
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?
Dec 01Financial Position Analysis
Short Term Liabilities: 4147's short term assets (NT$4.1B) exceed its short term liabilities (NT$722.4M).
Long Term Liabilities: 4147's short term assets (NT$4.1B) exceed its long term liabilities (NT$864.4M).
Debt to Equity History and Analysis
Debt Level: 4147 has more cash than its total debt.
Reducing Debt: 4147's debt to equity ratio has increased from 0% to 12.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 4147 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 4147 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 41.8% per year.